Korea's Ildong Pharmaceutical In Licensing Deal With Taiwan Liposome Firm To Sell Product In Korean Market
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ildong Pharmaceutical has signed a marketing and distribution agreement with Taiwan Liposome Company to sell the latter's arterial vasodilator and platelet-aggregation inhibitor ProFlow (alprostadil) - available as a generic - in Korea